Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities

被引:22
作者
Maher, Lisa [1 ,2 ]
White, Bethany [1 ,2 ]
Hellard, Margaret [3 ]
Madden, Annie [4 ]
Prins, Maria [5 ,6 ]
Kerr, Thomas [7 ]
Page, Kimberly [8 ]
机构
[1] Univ New S Wales, Ctr Immunol, Viral Hepatitis Epidemiol & Prevent Program, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia
[2] Univ New S Wales, Ctr Immunol, Sch Publ Hlth & Community Med, Darlinghurst, NSW 2010, Australia
[3] Macfarlane Burnet Inst Med Res, Ctr Populat Hlth, Melbourne, Vic 3004, Australia
[4] Australian Intravenous & Injecting League AIVL, Canberra, ACT 2600, Australia
[5] Univ Amsterdam, Acad Med Ctr, NL-1000 CE Amsterdam, Netherlands
[6] GGD Amsterdam Publ Hlth Serv, Dept Res, NL-1000 CE Amsterdam, Netherlands
[7] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada
[8] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA
基金
英国医学研究理事会;
关键词
Hepatitis C virus; Vaccine; People who inject drugs; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV VACCINE; B VACCINATION; PUBLIC-HEALTH; RISK-FACTORS; COST-EFFECTIVENESS; USERS; INFECTION; HCV; PREVENTION;
D O I
10.1016/j.vaccine.2010.08.085
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
People who inject drugs (PWID) are at high risk of HCV. Limited evidence of the effectiveness of prevention interventions and low uptake of treatment in this group highlight the need for increased investment in biomedical interventions, notably safe and efficacious vaccines. While several candidates are currently in development, field trials in PWID present challenges, including ethical issues associated with trial literacy, informed consent and standards of care. Significant biological and social factors and differences between HIV and HCV suggest that HCV warrants targeted vaccine preparedness research to lay the groundwork for successful implementation of future trials. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7273 / 7278
页数:6
相关论文
共 99 条
[41]   Supervised injecting facilities: time for scale-up? [J].
Kerr, Thomas ;
Montaner, Julio ;
Wood, Evan .
LANCET, 2008, 372 (9636) :354-355
[42]   Therapeutic vaccination of chronic hepatitis c nonresponder patients with the peptide vaccine IC41 [J].
Klade, Christoph S. ;
Wedemeyer, Heiner ;
Berg, Thomas ;
Hinrichsen, Holger ;
Cholewinska, Grazyna ;
Zeuzem, Stefan ;
Blum, Hubert ;
Buschle, Michael ;
Jelovcan, Sandra ;
Buerger, Vera ;
Tauber, Erich ;
Frisch, Juergen ;
Manns, Michael P. .
GASTROENTEROLOGY, 2008, 134 (05) :1385-1395
[43]   Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada [J].
Krahn, MD ;
John-Baptiste, A ;
Yi, QL ;
Doria, A ;
Remis, RS ;
Ritvo, P ;
Friedman, S .
VACCINE, 2005, 23 (13) :1549-1558
[44]  
Kuiken C, 2006, HEPATOLOGY, V44, p348A
[45]   The Impact of Needle and Syringe Programs on HIV and HCV Transmissions in Injecting Drug Users in Australia: A Model-Based Analysis [J].
Kwon, Jisoo A. ;
Iversen, Jenny ;
Maher, Lisa ;
Law, Matthew G. ;
Wilson, David P. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (04) :462-469
[46]   Focus on research: Challenges to HIV prevention - Seeking effective measures in the absence of a vaccine [J].
Lagakos, Stephen W. ;
Gable, Alicia R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (15) :1543-1545
[47]   Cross-genotype immunity to hepatitis C virus [J].
Lanford, RE ;
Guerra, B ;
Chavez, D ;
Bigger, C ;
Brasky, KA ;
Wang, XH ;
Ray, SC ;
Thomas, DL .
JOURNAL OF VIROLOGY, 2004, 78 (03) :1575-1581
[48]  
Lauer Georg M, 2007, Gastroenterology, V132, P1626, DOI 10.1053/j.gastro.2007.03.010
[49]  
Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35
[50]   Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? [J].
Levy, Vivian ;
Evans, Jennifer L. ;
Stein, Ellen S. ;
Davidson, Peter J. ;
Lum, Paula J. ;
Hahn, Judith A. ;
Page, Kimberly .
VACCINE, 2010, 28 (37) :5947-5951